A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Purpose: Investigate the safety of accelerated hypofractionated radiotherapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small-cell lung cancer (NSCLC). Patients and Methods: The primary objectives were to define the maximally tolerable course of accelerated radiotherapy and describe toxicities of therapy. Total radiotherapy remained at 60 Gy. The number of once daily fractions in each successive cohort was reduced. Cohort 1: 60 Gy 27 fx, Cohort 2: 60 Gy 24 fx, Cohortdoi:10.1016/j.ijrobp.2018.01.046 pmid:29487024 pmcid:PMC6173195 fatcat:kfvpurqttjherej3ziy35iqzaa